Information Provided By:
Fly News Breaks for October 2, 2017
CRIS
Oct 2, 2017 | 07:46 EDT
SunTrust analyst Peter Lawson believes there is a 70% chance that data on Curis' oral PD-L1 inhibitor CA-170 in solid tumors will include partial remissions. The analyst estimates that the stock will jump 25% if patients taking the drug have partial remissions, while the stock will fall 10% if there are no partial remissions. The analyst keeps a $3.50 price target and a Buy rating on the shares.
News For CRIS From the Last 2 Days
There are no results for your query CRIS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.